Company plans to meet with FDA regarding potential sNDA submission in 1H 2025Call planned today at 8:30 a.m. (ET) to discuss company's diabetes program progression DANBURY, Conn. and WESTLAKE VILLAGE ...

Millions of diabetes patients have to take a painful insulin injection to keep sugar levels in control. Cipla is introducing ...

Cipla secures CDSCO approval for Afrezza, its inhaled insulin, marking a breakthrough in diabetes management with innovative ...

New Delhi: Zydus Lifsciences has got approval from the Subject Expert Committee SEC functional under the Central Drug ...

Afrezza, world’s only rapid-acting, inhaled insulin for type 1 & type 2 diabetes patients & manufactured by MannKind, ...

Cipla to introduce Afrezza, an inhaled insulin for diabetes, offering convenience but not advised for lung-related concerns.

MannKind and Cipla announce CDSCO approves Afrezza inhalation powder in India: Our Bureau, Mumbai Thursday, December 12, 2024, 17:30 Hrs [IST] MannKind Corporation, a company focu ...

Mumbai: Cipla Limited has announced that it has obtained regulatory approval from Central Drugs Standard Control Organisation ...

Shares of firms like Jubilant FoodWorks, Maruti Suzuki, Swiggy, SBI, Vedanta, and others will be in focus on Thursday's trade ...

Greaves Cotton board approved OFS of certain shares of arm Greaves Electric held by the company in the proposed IPO.

Cipla has secured exclusive rights to distribute and market Afrezza, an inhalable insulin, in India. Developed by MannKind, ...

Cipla said it has received the nod from Central Drugs Standard Control Organisation (CDSCO) for the exclusive distribution and marketing of Afrezza - inhalation human insulin in India.